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Multidrug-resistant (MDR)-TB is threatening TB control worldwide. The conventional treatment lasts 
20–24 months, is often toxic and half of treated patients having poor outcomes. WHO have recently 
recommended a shorter regimen with treatment duration of 9–12 months, aiming for higher 
effectiveness, tolerability, adherence and completion rates.[1] This shorter regimen is recommended 
for patients with pulmonary TB who have not been previously exposed to second-line drugs for more 
than  one month and have no confirmed or suspected resistance to medicines in the regimen, except 
high-dose isoniazid. Recommendations were based on the promising results of large observational 
cohorts in Asia and Africa.  
 
In Thorax, Yanina Balabanova and colleagues assessed the proportion of adult smear-positive 
pulmonary MDR-TB cases who might have been eligible for the shorter regimen. The patients were 
initially recruited in 2007 and 2009 and followed up till 2012 in four eastern European countries, 
who participated in the European Union-funded TB-PAN-NET (Pan-European network for the 
study and clinical management of drug resistant tuberculosis) project.[2]  Given the drug sensitivity 
test results and the history of previous treatment with second-line drugs in this group of patients, 
the authors concluded that only 4.2% of the patients would have been eligible for the shorter WHO 
regimen. The results of this study were similar to other European and Latin American cohorts.[3] 
 
The WHO European region has one of the highest burdens of MDR-TB in the world with alarmingly 
high MDR-TB incidence rate and the highest proportions of MDR-TB among new and previously 
treated cases.[4] While the potential benefits of the shorter regimen on individual patients and 
healthcare systems cannot be underestimated, the effect might be minimal or even negative, given 
the lower treatment success rate and/or the high proportion of ineligible patients for the shorter 
course. 
 
As the authors state, the results of this study should be confirmed by similar evaluations in recent 
national surveillance projects. These might enable appropriate extrapolations for the region. Given 
the high prevalence of resistance to pyrazinamide and increasing rates of resistance to second-line 
drugs in the European region, there are concerns that a limited number of patients would fulfil the 
eligibility criteria for the shorter WHO regimen.  
 
The WHO guidelines highlight the need to exclude resistance to fluoroquinolones and injectables 
before starting treatment and promote rapid second-line molecular tests.[1] However, these tests 
are available only in central and regional-level laboratories, and therefore the use of the shorter 
regimen in practice may be limited to a few treatment centres with good access to diagnostics.  
Policy-makers are currently reluctant to implement a guidance with conditional recommendation 
and very low certainty in evidence, and are waiting for the definitive results of the STREAM 1 trial, an 
ongoing randomised controlled trial, directly comparing the efficacy and safety of the regimens.[5]  
 
The increasing prevalence of MDR-TB and limited access to drug-susceptibility testing make the 
pursuit for short, safe, affordable and injection-free regimens extremely important. The 9-12 month 
regimen is only a first step in the right direction. With few new and repurposed drugs registered, 
some drugs in development and a number of randomised controlled trials ongoing, hopefully 
definitive evidence for optimal MDR-TB treatment regimens will emerge in the near future. To 
establish that such regimens are fit for purpose in different geographical regions remains important 
if we are to avoid further development of antimicrobial resistance and poor outcome in the context 
of TB. 
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